What you’ll be listening to today is part one of that conversation, in which we will explore key 2022 trends that we expect to continue into 2023. We had a robust discussion that we are releasing as a four-part podcast series. I was joined by Kellie Combs, Josh Oyster, and Beth Weinman, from our life sciences regulatory and compliance practice group, and Margaux Hall, from our health care practice group. office to discuss our expectations for the coming year. Earlier this month, I sat down with several of my colleagues from our Washington, D.C. I’m Greg Levine, head of the life sciences regulatory and compliance practice group at Ropes & Gray, based in Washington, D.C. life sciences regulatory outlook podcast series. Greg Levine: Hello, and welcome to our 2023 U.S. Topics discussed include the Inflation Reduction Act, the Food and Drug Omnibus Reform Act (FDORA), possible legislative action related to orphan drug exclusivity, and the full resumption of domestic and international FDA inspections. This first episode will focus on key developments from 2022 that we expect to continue to be significant in 2023. and the potential impact on life sciences companies in 2023. Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. This episode of Ropes & Gray’s podcast series Non-binding Guidance examines the regulatory landscape for drug compounding and how it has evolved over the last 10 years since a 2012 nationwide fungal meningitis outbreak caused by contaminated drugs from the New England Compounding Center (NECC) rocked the industry and led to a legislative overhaul.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |